Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents

European Journal of Clinical Pharmacology

Volumn 65, Issue 12, 2009, Pages 1229-1235

  Gjerden, Pål ^a   Slørdal, Lars ^b,c   Bramness, Jørgen G ^d,e  

^a TELEMARK HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Adverse effects; Anticholinergic agents; Antiparkinson agents; Antipsychotic agents; Extrapyramidal side effects

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DIXYRAZINE; DOPAMINE 2 RECEPTOR; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; ORPHENADRINE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; THIORIDAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHOLINERGIC ANTAGONISTS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, DRUG;

EID: 71249083955     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0696-6     Document Type: Article

References (24)

1. J Geddes N Freemantle P Farrison P Bebbington 2000 Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis BMJ 321 1371 1376 10.1136/bmj.321.7273.1371 1:STN:280:DC%2BD3M7hsFSrsg%3D%3D 11099280
2. S Leucht K Wahlbeck J Hamann W Kissling 2003 New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis Lancet 361 1581 1589 10.1016/S0140-6736(03)13306-5 1:CAS:528:DC%2BD3sXjs1Wltbw%3D 12747876 (Pubitemid 36578993)
3. JM Davis N Chen ID Glick 2003 A meta-analysis of the efficacy of second-generation antipsychotics Arc Gen Psychiatry 60 553 564 10.1001/archpsyc.60.6.553 1:CAS:528:DC%2BD3sXltlKhtrc%3D (Pubitemid 36682312)
4. R Rosenheck D Perlick S Bingham W Liu-Mares J Collins S Warren D Leslie E Allan EC Campbell S Caroff J Corwin L Davis R Douyon L Dunn D Evans E Frecska J Grabowski D Graeber L Herz K Kwon W Lawson F Mena J Sheikh D Smelson V Smith-Gamble 2003 Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia JAMA 290 2693 2702 10.1001/jama.290.20.2693 1:CAS:528:DC%2BD3sXpsVaktLg%3D 14645311 (Pubitemid 37475597)
5. JA Lieberman TS Stroup JP McEvoy MS Swartz RA Rosenheck DO Perkins RSE Keefe SM Davis CE Davis BD Lebowitz J Severe JK Hsiao 2005 Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 1209 1223 10.1056/NEJMoa051688 1:CAS:528:DC%2BD2MXhtVeltL%2FN 16172203 (Pubitemid 41345943)
6. PB Jones TRE Barnes L Davies G Dunn H Lloyd KP Hayhurst RM Murray A Markwick SW Lewis 2006 Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia Arch Gen Psychiatry 63 1079 1087 10.1001/archpsyc.63.10.1079 1:CAS:528: DC%2BD28XhtFKhtrzP 17015810 (Pubitemid 44498387)
7. GWK Hugenholtz ER Heerdink JJ Stolker WEE Meijer ACG Egberts WA Nolen 2006 Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses J Clin Psychiatry 67 897 903 1:CAS:528:DC%2BD28XnsVamsrs%3D 16848649
8. van Kammen DP, Marder SR (2005) Serotonin-dopamine antagonists (atypical or second-generation antipsychotics). In: Sadock JB, Sadock VA (eds) Kaplan & Sadock's comprehensive textbook of psychiatry. Lippincott Williams & Wilkins, Philadelphia, pp 2914-2938
9. 2A receptor blockade CNS & Neurological Disorders-Drug Targets 5 445 445 10.2174/187152706777950693 1:CAS:528:DC%2BD28XnvFykt7g%3D
10. P Gjerden JG Bramness L Slørdal 2008 The use and potential abuse of anticholinergic antiparkinson drugs in Norway. A pharmacoepidemiological study Br J Clin Pharmacol 67 2 228 233 10.1111/j.1365-2125.2008.03342.x 19094158
11. K Furu H Strøm M Rønning S Skurtveit A Engedal A Tverdal 2005 The Norwegian Prescription Database (NorPD): new register for pharmacoepidemiological research covering a whole nation Pharmacoepidemiol Drug Saf 14 Suppl 2 S48
12. WHO Collaborating Centre for Drug Statistics Methodology (2005) Guidelines for ATC classification and DDD assignment. WHO, Oslo
13. WK Kroeze SJ Hufheisen BA Popadak SM Renock S Steinberg P Ernsberger K Jayathilake HY Meltzer BL Roth 2003 H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs Neuropsychopharmacology 28 519 526 10.1038/sj.npp.1300027 1:CAS:528: DC%2BD3sXhslyjt7Y%3D 12629531
14. R Tandon RH Belmaker WF Gattaz JJ Lopez-Ibor Jr A Okasha B Singh DJ Stein J-P Olie WW Fleishhacker H-J Moeller 2008 World psychiatric association pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia Schiz Res 100 20 38 10.1016/j.schres.2007.11.033
15. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. World Health Organization heads of centres collaborating in WHO co-ordinated studies on aspects of mental illness (1990) Br J Psychiatry 156:412
16. P Gjerden JG Bramness L Slørdal 2008 Effect of warnings in a medical journal on the use of orphenadrine J Eval Clin Pract 14 615 617 10.1111/j.1365-2753.2007.00912.x 18462287
17. Costa e Silva JA N Alvarez G Mazzotti WF Gattaz J Ospina V Larach S Starkstein D Oliva L Cousins M Tohen CC Taylor J Wang PV Tran 2001 Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: Results of a multicenter, collaborative trial in Latin America J Clin Psychopharm 21 375 381 10.1097/00004714-200108000-00004 (Pubitemid 32673026)
18. S Park D Ross-Degnan AS Adams J Sabin P Kanavos SB Soumerai 2005 Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia Br J Psychiatry 187 137 142 10.1192/bjp.187.2.137 16055824 (Pubitemid 41139685)
19. K Gao DE Kemp SJ Ganocy P Gajwani G Xia JR Calabrese 2008 Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia. A systematic review J Clin Psychopharm 28 203 209 10.1097/JCP.0b013e318166c4d5
20. WS Fenton 2000 Prevalence of spontaneous dyskinesia in schizophrenia J Clin Psychiatry 61 Suppl 4 10 14 10739325
21. WG Honer LC Kopala J Rabinowitz 2005 Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness J Psychopharmacol 19 3 277 285 10.1177/0269881105051539 1:CAS:528:DC%2BD2MXltlWju74%3D 15888513 (Pubitemid 40694946)
22. SN Ghaemi DJ Hsu KJ Rosenquist TB Pardo FK Goodwin 2006 Extrapyramidal side effects with atypical neuroleptics in bipolar disorder Prog Neuropsychopharmacol Biol Psychiatry 30 209 213 10.1016/j.pnpbp.2005.10.014 1:CAS:528:DC%2BD28XhvVWlu7k%3D 16412546 (Pubitemid 43288060)
23. DC Owens 2008 How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia Adv Psychiatr Treat 14 17 28 10.1192/apt.bp.107. 003970
24. S Leucht C Corves D Arbter RR Engel C Li JM Davis 2009 Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Lancet 373 31 41 10.1016/S0140-6736(08)61764-X 1:CAS:528:DC%2BD1MXht1Wqsw%3D%3D 19058842